Schedule online now
Follow Us On:

Early rosacea manifests as diffuse background erythema and flushing. In later stages, the vascular component is more prominent, with the development of telangiectasia on the nose, nasolabial folds, cheeks, glabella, and chin. Acneiform papules and pustules can emerge in the same distribution. More common in women, rosacea may be more severe in men,in whom large inflammatory nodules and soft-tissue hypertrophy may be disfiguring.

Ocular rosacea, including erythema and telangiectasia, is seen in over half of rosacea patients.

The pathogenesis of rosacea is not understood.
Recent reviews have repudiated the postulated association with Rosacea is treatable but not curable. Common rosacea triggers, such as sun, stress, hot weather, hot drinks, alcohol, and spicy foods, should be avoided by susceptible patients. Acneiform papules are typically improved by topical metronidazole, and nonresponders to this may benefit from topical clindamycin,other topical antibiotics, or sulfacetamide lotion. Topical corticosteroids must be applied cautiously, since long-term use can worsen telangiectasia and induce atrophy. Long-term oral antibiotic administration may be necessary to control papulopustules.

Surface vascularity in rosacea is minimally improved by medications. Pulsed-dye laser treatment remains the gold standard for treatment of redness, telangiectasia, and transient flushing. Historically, while patients were pleased with the final results of pulsed-dye laser, they were reluctant to receive this intervention because of the inevitability of one to two weeks of post-treatment purpura.
Difficult to conceal even with makeup, the dark purple color was embarrassing to patients in social and professional settings. New pulsed-dye lasers, such as the VB.

A purpura-free treatment is most effective for patients\ with diffuse redness or pinkness but no large, individually visible blood vessels. Very fine, discrete telangiectasia also respond well to purpurafree treatment. After signing an informed consent for pulsed-dye laser treatment, patients were reated with the Vbeam at the highest fluence possible without inducing purpura. In most cases, this required the 10 ms pulse duration, the 10 mm spot size, and fluences ranging from 6 to 7.5 J/cm. The redder the face, the lower the threshold for purpura, and hence the fluence.

The entire involved area was treated during each laser session. The number of pulses depended on the total area. On average, each patient received three treatments at six-week intervals.



Candela Syneron
Candela Laser Corporation is a top American medical aesthetic laser device manufacturer founded in 1970. For over 40 years, Candela has been developing and selling medical laser devices and has established its position as a global leader dedicated to elevating the medical aesthetics industry as a whole.